| Variable | No. of patients (%) | p value | |
|---|---|---|---|
| Suicide death n = 82 | Nonsuicide death n = 911 | ||
| Sex | |||
| Female | 18 (22) | 194 (21) | 0.9 |
| Male | 64 (78) | 717 (79) | |
| Ethnicity | |||
| Aboriginal | 16 (20) | 195 (21) | 0.9 |
| Non-Aboriginal | 24 (29) | 267 (29) | |
| Unknown | 42 (51) | 449 (49) | |
| Geographic region | |||
| Rural | 2 (2) | 42 (5) | 0.75 |
| Urban | 64 (78) | 699 (77) | |
| Unknown | 16 (20) | 170 (19) | |
| History of injection drug use | |||
| Yes | 47 (57) | 449 (49) | 0.1 |
| No | 10 (12) | 196 (22) | |
| Unknown | 25 (30) | 266 (29) | |
| AIDS-defining illness | |||
| Yes | 4 (5) | 296 (32) | < 0.001 |
| No | 78 (95) | 615 (68) | |
| Hepatitis C | |||
| Yes | 63 (77) | 548 (60) | 0.01 |
| No | 13 (16) | 250 (27) | |
| Unknown | 6 (7) | 113 (12) | |
| Last or most recent HAART regimen | |||
| Single PI | 47 (57) | 537 (59) | 0.4 |
| Single NNRTI | 30 (37) | 281 (31) | |
| Any IIN | 0 (0) | 25 (3) | |
| Other | 5 (6) | 68 (7) | |
| Efavirenz included in last or latest regimen | |||
| Yes | 7 (9) | 142 (16) | 0.1 |
| No | 75 (91) | 769 (84) | |
| Adherence | |||
| ≥ 95% | 19 (23) | 197 (22) | 0.8 |
| < 95% | 63 (77) | 714 (78) | |
| Age at death, yr; median (IQR) | 42 (38–49) | 46 (39–54) | < 0.001 |
| Year of death, median (IQR) | 2003 (2000–2006) | 2006 (2002–2009) | < 0.001 |
| Median income, CAD (IQR) | 21 015 (14 750–27 799)† | 19 346.5 (14 518–26 073)‡ | 0.7 |
| Baseline CD4+ cell count, × 109/L; median (IQR) | 0.29 (0.17–0.4) | 0.15 (0.05–0.27) | < 0.001 |
| Last or most recent CD4+ cell count before the end of follow-up, × 109/L; median (IQR) | 0.355 (0.2–0.5) | 0.14 (0.03–0.31) | < 0.001 |
| Nadir CD4+ cell count, × 109/L; median (IQR) | 0.17 (0.07–0.29) | 0.05 (0.01–0.14) | < 0.001 |
| Last or most recent viral load before the end of follow-up,* log10 copies/mL; median (IQR) | 5.0 (2.69–5.0) | 5 (2.69–5.0) | 0.5 |
| No. of years of treatment with HAART, yr; median (IQR) | 3 (2–6) | 3 (1–6) | 0.5 |
Note: HAART = highly active antiretroviral therapy, IIN = integrase inhibitor, IQR = interquartile range, NNRTI = non-nucleoside reverse-transcriptase inhibitor, PI = protease inhibitor. *End of follow-up can be the date of death, the last date of contact, last date of contact date before moving out of British Columbia or to participation in antiretroviral blinded trials. †Some values for income were missing. Median income was calculated using n = 65. ‡Some values for income were missing. Median income was calculated using n = 700.